This work is licensed under the Creative Commons Attribution 4.0 International License.
Cohen AT, Agnelli G, Anderson FA, et al. VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756-64.Search in Google Scholar
White RH. The epidemiology of venous thromboembolism. Circulation. 2003 Jun 17;107(23 Suppl 1):I4-8.Search in Google Scholar
Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1-7.Search in Google Scholar
Heit JA, Mohr DN, Silverstein MD et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160(6):761-8.Search in Google Scholar
Kahn SR, Kearon C, Julian JA, et al. Extended Low-intensity Anticoagulation for Thrombo-embolism (ELATE) Investigators. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost. 2005;3(4):718-23.Search in Google Scholar
Ageno W, Piantanida E, Dentali F, Steidl L, Mera V, Squizzato A, Marchesi C, Venco A. Body mass index is associated with the development of the post-thrombotic syndrome. Thromb Haemost. 2003;89(2):305-9.Search in Google Scholar
Ashrani AA, Heit JA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis. 2009;28(4):465-76.Search in Google Scholar
Sud R, Khorana AA. Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res. 2009;123 Suppl 4:S18-21.Search in Google Scholar
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 19;127(20):2391-405.Search in Google Scholar
Takenaka K, Shimoda K, Akashi K. Recent advances in the diagnosis and management of primary myelofibrosis. Korean J Intern Med. 2018;33(4):679-90.Search in Google Scholar
Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89-101.Search in Google Scholar
Barbui T, Carobbio A, Cervantes F,et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778-82.Search in Google Scholar
Murphy IG, Mitchell EL, Raso-Barnett L,et al. Imaging features of myeloproliferative neoplasms. Clin Radiol. 2017; Oct;72(10):801-9.Search in Google Scholar
Policitemia GIS. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995 Nov 1;123(9):656-64Search in Google Scholar
Le Bousse-Kerdilès MC. Primary myelofibrosis and the „bad seeds in bad soil” concept. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S20.Search in Google Scholar
Klampfl T, Gisslinger H, Harutyunyan AS et al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N Engl J Med. 2013 Dec 19;369(25):2379-90.Search in Google Scholar
Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-405.Search in Google Scholar
Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 1;29(4):392-7.Search in Google Scholar
Verstovsek S et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10(1):156.Search in Google Scholar
Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol. 2018 15;11(1):42.Search in Google Scholar
Benjamini O, Jain P, Estrov Z,et al. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood. 2012 Sep 27;120(13):2768-9.Search in Google Scholar
Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016 Dec;91(12):1262-71Search in Google Scholar
Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-98.Search in Google Scholar
Yacoub A, Odenike O, Verstovsek S. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms. Curr Hematol Malig Rep. 2014;9(4):350-9.Search in Google Scholar
Product Information Jakavi (ruxolitinib). Available on: https://www.ema.europa.eu/en/documents/product-information/jakaviepar-product-information_en.pdf, accessed on 13.03.2021Search in Google Scholar
Kaifie, A et al. “Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.” Journal of Hematology & Oncology 2016 9; 18.Search in Google Scholar
Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia. 2012;26(4):563–71.Search in Google Scholar
Kreher S, Ochsenreither S, Trappe RU, Pabinger I, Bergmann F, Petrides PE, et al. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.) Annals of Hematology. 2014;93(12):1953–63Search in Google Scholar
Tefferi, A. & Barbui, T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2017. 92, 94–108.Search in Google Scholar
Barbui, T. et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia.2008. 32, 1057–1069, https://doi.org/10.1038/s41375-018-0077-1.Search in Google Scholar
De Stefano, V. et al. GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008 Mar;93(3):372-80.Search in Google Scholar
Hernández-Boluda, J. C. et al. Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol. 2015 Jun;94(6):911-8.Search in Google Scholar
De Stefano, V. et al. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia. 2016 Oct;30(10):2032-8Search in Google Scholar
De Stefano, V., Finazzi, G. & Barbui, T. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasm. Blood Cancer J. 2018 Jun 26;8(7):65.Search in Google Scholar
Cervantes F, Alvarez-Larrán A, Arellano-Rodrigo E,et al. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia. 2006;20(1):55-60Search in Google Scholar
Kc D, Falchi L, Verstovsek S. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol. 2017 Oct;96(10):1595-604Search in Google Scholar
Kuijper PH, Gallardo Torres HI, Lammers JW, Sixma JJ, Koenderman L, Zwaginga JJ. Platelet and fibrin deposition at the damaged vessel wall: cooperative substrates for neutrophil adhesion under flow conditions. Blood. 1997 Jan 1;89(1):166-75.Search in Google Scholar
Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC,et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2):169-75.Search in Google Scholar
Alvarez-Larrán A, Arellano-Rodrigo E, Reverter JC,et al. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol. 2008;87(4):269-76.Search in Google Scholar
Giannitrapani L, Granà W, Licata A, et al. Nontumorous Portal Vein Thrombosis in Liver Cirrhosis: Possible Role of β-Blockers. Med Princ Pract. 2018;27(5):466-71.Search in Google Scholar
Xu X, Guo X, De Stefano V, et al. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int. 2019 Jul;13(4):468-81Search in Google Scholar
Xu X, Xu S, Primignani M, et al. Nonselective β-Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study. Adv Ther. 2020 Apr;37(4):1452-63.Search in Google Scholar
